Titre :

Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID.

Auteur(s) :

Amiot, Aurélien [Auteur]
Hôpital Henri Mondor
Seksik, Philippe [Auteur]
CHU Saint-Antoine [AP-HP]
Reimund, Jean-Marie [Auteur]
Interface de Recherche Fondamentale et Appliquée en Cancérologie [IRFAC - Inserm U1113]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Altwegg, Romain [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Bourreille, Arnaud [Auteur]
Institut des Maladies de l'Appareil Digestif
Viennot, Stephanie [Auteur]
CHU Caen
Fumery, Mathurin [Auteur]
Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV [PERITOX]
Roblin, Xavier [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Serrero, Melanie [Auteur]
Aix Marseille Université [AMU]
Allez, Matthieu [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Painchart, Claire [Auteur]
Centre hospitalier [Valenciennes, Nord]
Chanteloup, Elise [Auteur]
Centre hospitalier Saint-Joseph [Paris]
Vuitton, Lucine [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Fotsing, Ginette [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Buisson, Anthony [Auteur]
CHU Clermont-Ferrand
Coulibaly, Baya [Auteur]
Centre Hospitalier Henri Duffaut (Avignon)
Nancey, Stephane [Auteur]
Hospices Civils de Lyon [HCL]
Gilletta, Cyrielle [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Plastaras, Laurianne [Auteur]
CH Colmar
Abitbol, Vered [Auteur]
Hôpital Cochin [AP-HP]
Guillo, Lucas [Auteur]
Institut Mutualiste de Montsouris [IMM]
Simon, Marion [Auteur]
Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
Nahon, Stephane [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Laharie, David [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Peyrin-Biroulet, Laurent [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Bouguen, Guillaume [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]

Titre de la revue :

Digestive and Liver Disease

Nom court de la revue :

Dig Liver Dis

Numéro :

54

Pagination :

1350-1357

Date de publication :

2022-05-26

ISSN :

1878-3562

Mot(s)-clé(s) en anglais :

Anti-TNF
Contraindication
Crohn?s disease
Inflammatory bowel disease

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background The exact rate of contraindications to anti-TNF therapy and physician perspectives on treatment choices facing to anti-TNF contraindication, are poorly reported. Methods A two-week cross-sectional study was ...
Lire la suite >Background The exact rate of contraindications to anti-TNF therapy and physician perspectives on treatment choices facing to anti-TNF contraindication, are poorly reported. Methods A two-week cross-sectional study was conducted in 31 centres. Physicians completed a questionnaire for a total of 1,314 consecutive outpatients with Crohn's disease, assessing each patient's potential contraindications to anti-TNF therapy, the choice of alternative therapy to anti-TNFs, and their preference in an unrestricted reimbursement setting. Results Among the 1,293 responses to the first item, 148 (11.5%) reported 32 absolute contraindications (2.5%) and 116 relative contraindications (9.0%) to anti-TNF therapy. When asked about their preference of alternative therapies in those cases with contraindications to anti-TNF, physicians chose ustekinumab and vedolizumab, 75.6% and 23.9%, respectively. In multivariable analysis, the choice of vedolizumab was the preferred choice for patients aged > 60 years with the L2 phenotype and the absence of perianal lesions. In a hypothetical setting of unrestricted reimbursement, anti-TNFs remained physicians’ preferred first-line biological therapy choice for 78.2%. Conclusion Anti-TNF contraindications occurred in up to 11.5% of patients with Crohn's disease. Physicians’ choices for alternative therapy to anti-TNF relied on ustekinumab in 75.6% and vedolizumab in 23.9% of these cases. This choice was driven mainly by phenotypical criteria and age.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T01:28:42Z
2024-03-19T12:32:38Z